SCHEMBL7797913

SCHEMBL7797913

CCOc1cc(OC)c(C(=O)Nc2cccc3c2CCNC3CCO)cc1Br

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40
LMNA P02545 5/20 0.38
MAPT P10636 4/20 0.38
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 3/20 0.38
HTT P42858 1/20 0.38
NPSR1 Q6W5P4 3/20 0.38
HPGD P15428 2/20 0.38
TSHR P16473 1/20 0.38
ATM Q13315 1/20 0.38
HSD17B10 Q99714 1/20 0.38
OPRM1 P35372 1/20 0.37
KCNK3 O14649 1/20 0.37
KCNK9 Q9NPC2 1/20 0.37
S1PR1 P21453 1/20 0.37
TP53 P04637 1/20 0.37
POLB P06746 3/20 0.36
RXFP1 Q9HBX9 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8077366 0.86 RXFP1 (0.40) CYP3A4MAPTALDH1A1TSHRHSD17B10
SCHEMBL7978729 0.78 KDM4E (0.45) CYP3A4CYP2C9CYP2C19LMNAMAPT
SCHEMBL7797917 0.75 SIGMAR1 (0.44) MEN1KMT2A
SCHEMBL7797970 0.74 KMT2A (0.42) LMNAMAPTKDM4ENPSR1HPGD
SCHEMBL7993247 0.72 KDM4E (0.43) CYP3A4CYP2C9CYP2C19LMNAMAPT
SCHEMBL7799778 0.71 MEN1 (0.46) CYP3A4CYP2C19LMNAMAPTALDH1A1
SCHEMBL7993464 0.70 KMT2A (0.42) LMNAMAPTALDH1A1KDM4ENPSR1
SCHEMBL7802393 0.69 KMT2A (0.44) LMNAMAPTALDH1A1HSD17B10POLB
Hydrochloric Acid SCHEMBL7797935 0.68 KMT2A (0.43) LMNAMAPTALDH1A1HSD17B10POLB
SCHEMBL6295126 0.68 MAPT (0.53) CYP3A4CYP2C9CYP2C19LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants SMITHKLINE BEECHAM P.L.C. 2001-09-27 US disclosed
EP-1025087-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 2000-08-09 EP disclosed
WO-1999021836-A1 SUBSTITUTED ISOQUINOLINE DERIVATIVES AND THEIR USE AS ANTICONVULSANTS SMITHKLINE BEECHAM PLC (GB) 1999-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010025045-A1 Substituted isoquinoline derivatives and their use as anticonvulsants INA, GRIN2C, GRIN2A CYP3A4 168/4885CYP2C9 481/4885CYP2C19 658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.